New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 27, 2014
12:35 EDTDB, RHI, CAT, CRARY, GERN, GAME, CRZBY, XRX, MRKOn The Fly: Midday Wrap
Stocks on Wall Street were lower at midday as a decline in new home sales last month more than offset any positive momentum built in the early hours by Caterpillar's (CAT) better than expected earning report. Stocks began the week in positive territory, briefly bouncing back from last week’s sell-off, but the market resumed its downward trend by the time the larger than expected drop in new home sales was reported near 10 am ET. As the lunch hour approached, the averages were all in the red and stood near session lows. ECONOMIC EVENTS: In the U.S., new home sales dropped 7% to a 414K rate in December from a downwardly revised 445K rate in November, missing expectations. However, the report may have been somewhat discounted as largely due to the extreme weather seen in many markets during the month. In Europe, the Ifo institute’s German business confidence measure beat economists’ forecasts and rose to its highest level in more than two years with a 110.6 reading in January. Also, the Organization for Economic Cooperation and Development reportedly estimated that European banks have a combined capital shortfall of about 84 billion euros, with Credit Agricole (CRARY), Deutsche Bank (DB) and Commerzbank (CRZBY) listed among the banks having significant gaps. COMPANY NEWS: Dow component Caterpillar advanced about 4% after its quarterly earnings easily beat the consensus expectation of analysts. The company also gave a forecast for revenue in the new fiscal year that surpassed expectations and approved a program to repurchase up to $10B of its shares. MAJOR MOVERS: Among the notable gainers was Chinese online game maker Shanda Games (GAME), which gained 13% after its controlling shareholder proposed to acquire the company in a "going private" transaction for $6.90 per American depositary share. Also higher was Robert Half (RHI), which rose 3% following an upgrade to Buy from Neutral at research firm Northcoast, which cited the valuation of its shares and expectations for top-line trends to accelerate due to easier comparisons and improving end markets. Also higher following an upgrade were shares of Merck (MRK), which gained nearly 3% after Morgan Stanley upgraded the stock two notches to Overweight from Underweight. Among the noteworthy losers was Geron (GERN), which fell 19% after disclosing that an investigator-sponsored clinical trial to evaluate imetelstat in patients with myelofibrosis and other myeloid malignancies has been closed to new patient enrollment and that the company believes approximately 20 patients have discontinued from the study since its inception. Also lower were shares of Xerox (XRX), which were downgraded to Market Perform from Outperform at BMO Capital and slid almost 5% near noon. INDEXES: Near midday, the Dow was down 76.11, or 0.48%, to 15,803.00, the Nasdaq was down 69.13, or 1.67%, to 4,059.04, and the S&P 500 was down 15.10, or 0.84%, to 1,775.19.
News For CAT;MRK;GAME;RHI;XRX;GERN;DB;CRZBY;CRARY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
January 27, 2015
07:39 EDTCATCaterpillar cites dramatic decline in oil for lower outlook
Subscribe for More Information
07:35 EDTCATCaterpillar drops 5% after FY15 outlook misses expectations
Subscribe for More Information
07:34 EDTCATCaterpillar sees FY15 EPS ex-items about $4.75, consensus $6.67
Subscribe for More Information
07:32 EDTCATCaterpillar reports Q4 EPS ex-items $1.35, consensus $1.55
Subscribe for More Information
06:52 EDTDBEuropean Central Bank raises capital requirements for banks, WSJ says
Subscribe for More Information
January 26, 2015
15:50 EDTCATCaterpillar January weekly 85 straddle priced for 4.4% movement into Q4
Subscribe for More Information
15:40 EDTCATNotable companies reporting before tomorrow's open
Subscribe for More Information
14:59 EDTCATCaterpillar technical comments ahead of earnings
Subscribe for More Information
13:15 EDTCATEarnings Preview: Caterpillar sees Q4 profitability down slightly
Subscribe for More Information
11:08 EDTCATCaterpillar reports retail machines sales down 12% in three months end December
Caterpillar reported earlier its total retail machines sales down 12% on a three month rolling basis in December. Sales were down 10% in the period ending in November and were down 9% in the period ending in October. The company reported world Resources Industries sales down 22% in the December period, which was a bit improved from the 23% drop in the November end period. Construction Industries world sales were down 9%, worse than the 6% drop in the November period. Caterpillar retail sales of machines by geographic region for the 3-month rolling period ended December were reported in a regulatory filing earlier. Caterpillar shares are up 0.4% to $85.96 in morning trading.
09:57 EDTCATCaterpillar January weekly volatility elevated into Q4 and outlook
Subscribe for More Information
08:31 EDTMRKMerck says CHMP issues positive opinion for Sivextro
Merck announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending approval of the investigational antibiotic SIVEXTRO for the treatment of acute bacterial skin and skin structure infections in adults. Merck acquired SIVEXTRO as a part of its purchase, through a subsidiary, of Cubist Pharmaceuticals, Inc. The CHMP positive opinion will be reviewed by the European Commission. If the European Commission affirms the CHMP opinion, it will grant a centralized marketing authorization with unified labeling that is valid in the 28 countries that are members of the European Union, as well as European Economic Area members, Iceland, Liechtenstein and Norway. SIVEXTRO is a once-daily oxazolidinone antibiotic developed for both intravenous and oral administration for the treatment of serious infections caused by certain Gram-positive bacteria.
08:17 EDTXRXXerox well positioned in 2015, says Brean Capital
Subscribe for More Information
January 23, 2015
06:39 EDTMRKNIH, GlaxoSmithKline, Merck launch joint Ebola vaccine test in Liberia, WSJ says
Subscribe for More Information
January 21, 2015
10:16 EDTMRKLeerink biopharma analysts hold an analyst/industry conference call
Analyst Fernandez, along with Dr. Paul Gurbel and Dr. Richard Becker, discuss AstraZeneca's PEGASUS trial and the current use of Brilinta and dual antiplatelet therapy for prevention of CV disease and implications of the recently completed DAPT trial on an Analyst/Industry conference call to be held on January 21 at 1:30 pm.
08:07 EDTXRXXerox, Thinfilm announce strategic partnership
Subscribe for More Information
08:02 EDTMRKMerck completes tender offer to acquire Cubist
Merck (MRK) announced the successful completion of the tender offer for all of the outstanding shares of common stock of Cubist Pharmaceuticals (CBST) at a purchase price of $102.00 per share. As of the tender offer expiration yesterday, 58,039,667 shares of common stock of Cubist were validly tendered and not properly withdrawn from the tender offer, representing approximately 75.7% of the outstanding common stock of Cubist on a fully diluted basis. All of such shares have been accepted for payment in accordance with the terms of the tender offer, and Merck expects to promptly pay for all such shares. Following consummation of the tender offer, Merck expects to complete the acquisition of Cubist later today through a merger of Merck’s wholly owned subsidiary with and into Cubist without stockholder approval. Upon completion of the merger, all outstanding shares of common stock of Cubist, other than shares held by Cubist in treasury or shares held by Cubist’s stockholders who are entitled to and properly exercise appraisal rights under Delaware law, will be canceled and converted into the right to receive cash equal to the $102.00 offer price per share without interest, less any applicable withholding taxes. In addition, upon completion of the merger, Cubist will become a wholly owned subsidiary of Merck and the common stock of Cubist will cease to be traded on the NASDAQ Stock Market.
07:43 EDTCATCaterpillar guidance expected to disappoint, says UBS
UBS sees many headwinds for Caterpillar, including lower oil prices, slowing construction activity, and foreign currency headwinds. Although the firm feels the risks are already priced into the stock, they lowered estimates and expect forward guidance to be disappointing. UBS reiterated its Neutral rating but lowered its price target to $84 from $104 on Caterpillar shares.
January 20, 2015
17:18 EDTMRKDana Holding to replace Cubist in S&P 400 as of 1/22 close
Subscribe for More Information
07:23 EDTMRKMerck funding testing of lower dosages of Zilmax, Reuters reports
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use